For more than three decades, the 340B Drug Pricing Program operated within a relatively stable and predictable framework. Covered entities purchased drugs at a discounted ceiling price, manufacturers applied that price through pharmaceutical chargebacks, and downstream risks such as duplicate discounts were managed through established reconciliation workflows. Pricing was settled at the point of transaction, and validation followed within well-defined structures.
With the new 340B rebate model, the usual predictability is changing, creating new challenges for manufacturers in following rules, keeping track of finances, and managing claims.
OLD MODEL (Chargeback)
Manufacturer → Distributor → Covered Entity
(Discount applied upfront via chargeback mechanism)
NEW MODEL (Rebate)
Manufacturer → Distributor → Covered Entity (WAC) → Claim Submission → Manufacturer Validates → Rebate Payment to Covered Entity
Today, with this model, covered entities procure drugs at Wholesale Acquisition Cost (WAC) and submit rebate claims to manufacturers for reimbursement of the difference between WAC and the applicable 340B ceiling price. Manufacturers validate each claim before issuing a rebate, and each evaluation depends on adherence to multiple conditions. Here, pricing depends on what the data confirms after the transaction, rather than what was agreed at the point of sale, making rebate compliance increasingly dependent on accurate, timely claim validation. This shifts the entire control burden to post-dispense operations, an area where most manufacturer systems were not built to manage and operate claims at scale.
For manufacturers, such suboptimal systems would result in longer conflict resolutions, reconciliation gaps that surface late, and financial exposure that is difficult to track with confidence. Subsequently, on a broader business aspect, this means delayed visibility into liabilities, increased operational overhead, and greater risk of financial misstatement.
The Data Ecosystem Behind Every Claim
The data required to validate a 340B rebate claim sits across multiple systems, each contributing a different part of the transaction.
Third-party Administrators (TPAs) manage contract pharmacy relationships, while Pharmacy Benefit Managers (PBMs) provide transaction feeds, and wholesalers track distribution. At the same time, internal government pricing platforms handle pricing logic, Medicaid systems carry rebate exposure data, and covered entities submit claim files.
The systems liable for the above functions will deliver the intended outcomes within the scope. But the challenge is that they operate independently, resulting in a lack of holistic alignment.
Eligibility may be confirmed in one system, dispense details exist in another, and rebate obligations sit in a third. Because these systems use different identifiers, formats, and update timelines, validating a claim requires bringing multiple data elements together, such as covered entity eligibility, dispense details, pricing inputs, and Medicaid indicators, to ensure each claim is evaluated accurately and consistently.
Without this alignment, validation depends on manual reconciliation between datasets that do not naturally fit together, slowing operations, increasing effort, and making 340B rebate validation harder to scale with confidence.
Where Operations Break Down
These gaps surface at key touchpoints in the validation process, where data misalignment and timing issues affect claim outcomes.
Eligibility validation gaps
Covered entity eligibility is not static. Sites are added, removed, or updated through Health Resources and Services Administration (HRSA) recertification cycles and updates to the Office of Pharmacy Affairs (OPA) database. When internal/subsequent systems do not reflect those changes in a timely manner, claims may be denied or approved based on outdated information.
For instance, a claim submitted for a child site that was recently added but not yet reflected in the manufacturer’s eligibility dataset may be denied based on stale data. Resolving this requires more effort than correcting the outcome. The manufacturer must demonstrate which eligibility dataset was in use, when it was last updated, and how the validation rule was applied at that point. Without that level of traceability, disputes default to manual intervention and rarely close cleanly, increasing the need for structured 340B internal audit checklist and processes.
Duplicate discount validation
Manufacturers must ensure that a unit is not subject to both a 340B rebate and a Medicaid rebate. Maximum Fair Price (MFP) non-duplication requirements add another layer, requiring coordination with Medicaid Exclusion File (MEF) logic and adherence to 340B pricing compliance expectations.
The core problem is timing. Medicaid data often arrives after the initial rebate validation window, meaning a claim approved on available data may later surface a Medicaid overlap. As a result, claims approved on incomplete data may later require reversal, reprocessing, and financial adjustment. Without consistent matching logic, duplicate discount detection becomes unreliable at the volumes generated by rebate models.
Claim data inaccuracies
When corrected data arrives and the claim is reprocessed, the absence of a precise record of the original submission creates confusion, delays, and repeated effort. This leads to repeated validation cycles, inconsistent outcomes, and increased dependency on manual intervention.
What makes these scenarios manageable is maintaining an exact record of the data received, how it was interpreted, and the decision made at each step. Short of that, the same issues recur across claim cycles from submission and validation to rejection, reprocessing, and final payment, making consistency harder to maintain at scale.
Why These Challenges Persist
The common thread across all three breakdowns is the lack of a cohesive and seamless structure.
Validation depends on data distributed across TPAs, PBMs, wholesalers, Medicaid systems, and internal platforms, but with no single system acting as the source of truth.
Ownership is fragmented across market access, finance, compliance, and IT, limiting end-to-end visibility and slowing decision-making.
Issues do not resolve fully in that environment; they keep resurfacing.
Fixing them requires rethinking the operating model, not patching individual failures.
Building a Connected Operating Model
The solution for this evolving 340B rebate model is to build an infrastructure that connects data, validation, reconciliation, and financial controls at the claim level.
The goal is simple: ensure every function operates from the same record, and every decision can be clearly explained.
The sections below walk through specific areas where that infrastructure is built, from unifying data across contributing systems to enabling coordinated decision-making across functions
1. Establish a unified data layer across all contributing systems
A consistent validation and reconciliation process depends on how data is structured and accessed.
A unified data layer is built by integrating data streams from TPAs, PBMs, wholesalers, and internal platforms into a standardized model.
This is typically done through API-based integrations and batch ingestion pipelines, with transformation logic applied to align identifiers and formats. Data quality checks are applied at ingestion to flag inconsistencies early.
As a result, downstream processes operate on a consistent dataset, reducing the need for manual data alignment and enabling scalability.
2. Standardize validation across systems and data sources
With a unified data foundation in place, validation can be applied consistently across all claims.
Validation consistency is achieved by routing incoming claim data through a centralized rules engine. As data arrives from different sources, identifiers such as NDCs and covered entity IDs are normalized into a common format. Validation rules are then applied in sequence like eligibility checks, contract pharmacy alignment, and duplicate discount logic aligned with Medicaid and MFP requirements.
This ensures that every claim is evaluated using the standardized logic, regardless of source or timing, improving consistency in outcomes.
3. Move reconciliation closer to real-time operations
Once claims are validated, the next step is to ensure they remain aligned with external data and financial records.
Reconciliation is embedded into the claim processing flow rather than handled separately. As claims are validated, they are simultaneously matched against payment records and external datasets such as Medicaid rebate data. When new data becomes available, the system re-evaluates impacted claims, flagging mismatches through exception workflows.
This creates a continuous reconciliation process in which discrepancies are identified early and addressed with clear context, rather than accumulating until the period closes. Over time, the approach supports more predictable financial processes.
4. Strengthen Gross-to-Net (GTN) control through direct linkage to claim activity
As reconciliation becomes more continuous, financial alignment becomes a critical layer.
Claim validation outcomes feed directly into accrual calculations, allowing systems to distinguish between validated liabilities and provisional exposure in close to real time. For GTN teams, this process changes how accruals are managed.
Rather than relying on period-end true-ups, financial positions adjust as claim status changes, creating a more direct connection between operational activity and financial reporting.
5. Gain complete visibility into every claim decision
With validation, reconciliation, and financial alignment connected, visibility into each claim becomes more structured.
In many environments, understanding a claim decision requires piecing together information from multiple systems. This is addressed by capturing claim data as it enters the system and maintaining a continuous record as it moves through validation. Each step, from data ingestion and transformation to rule execution and decision outcome, is logged with timestamps and linked back to the source systems.
This creates a traceable claim journey, enabling teams to understand not just the final decision but also how it was reached. It supports structured dispute handling and audit readiness without manual reconstruction.
6. Enable coordinated decision-making across functions
With clear visibility in place, teams can act on insights more effectively.
Rebate operations span market access, finance, compliance, and IT. Shared access to claim-level data and decisions through dashboards and workflow tools enables better coordination across these functions.
As claims move through validation and reconciliation, their status is visible across teams. Exception workflows assign ownership and track resolution, ensuring that issues are addressed within defined processes.
This improves coordination in practical terms, reducing reliance on fragmented communication and enabling more consistent decision-making.
7. Use automation and analytics to improve performance over time
As the operating model stabilizes, automation and analytics play a key role in scaling and improving performance.
Automation ensures that validation and reconciliation steps are executed consistently across all claims, reducing manual effort and inconsistencies. Analytics provides visibility into patterns such as recurring validation failures, data inconsistencies, and timing gaps across systems.
It allows organizations to address root causes rather than repeatedly resolving similar issues. Over time, this supports improvements in data quality, process efficiency, and operational control.
Enabling Control, Visibility, and Scale in the 340B Rebate Model
As the 340B rebate model evolves, the focus shifts from defining the right operating model to making it work reliably at any scale.
This is where SRM Tech comes in.
We work with life sciences manufacturers to translate the connected, claim-level model into practical, day-to-day operations, ensuring that validation, reconciliation, and financial tracking remain aligned as volumes grow and data complexity increases.
Our approach is grounded in deep Government Pricing expertise and hands-on experience with rebate-based 340B program management and operations. And as a Model N advisory and implementation partner, with data engineering capabilities, we facilitate a streamlined market access ecosystem that connects information from TPAs, PBMs, wholesalers, Medicaid systems, and internal platforms.
This foundation is strengthened by our pre-built frameworks for validation, reconciliation, and dispute support, enabling faster implementation while maintaining consistency across claim processing. At the same time, audit-ready traceability, reporting accelerators, and governance dashboards ensure that every claim is supported by clear visibility and ongoing control.
Our delivery is structured through a collaborative model that brings together domain, operational, and technology expertise, ensuring that solutions are not only designed effectively but also embedded seamlessly into existing environments.
We ensure that the impact is visible across operations:
- Disputes are easier to resolve and close with confidence
- Reconciliation becomes more predictable and less reactive
- Financial exposure is identified earlier and managed with greater accuracy
With these in place, teams across Market Access, Finance, Compliance, and IT operate with a holistic view of claim activity, enabling more coordinated and consistent decision-making.
Whether supporting organizations already managing rebate operations or preparing for expansion, we help you assess your current state and define a clear path forward. Connect with our life sciences experts and 340B audit consultants to evaluate your 340B rebate operations and identify opportunities to improve control, reduce risk, and enhance financial visibility.
Frequently Asked Questions
What does the 340B ruling mean for drug rebate models?
The 340B ruling is accelerating the shift from upfront discounts to rebate-based models, where covered entities purchase drugs at full price and later submit claims for reimbursement. This increases the need for claim validation, reconciliation, and audit-ready tracking across manufacturers and healthcare providers.
How do drug rebates work?
Drug rebates are post-purchase payments made by manufacturers to eligible entities based on predefined pricing agreements. In the 340B rebate model, covered entities purchase drugs at full price, submit claims, and receive rebates after manufacturer validation.
What is the difference between 340B and rebates?
The 340B program is a federal pricing program that requires manufacturers to provide discounted outpatient drugs to eligible healthcare organizations. A rebate is the payment mechanism increasingly being used within the 340B model to reimburse covered entities after purchase.
What is the purpose of the 340B program?
The 340B program helps eligible safety-net hospitals and clinics access outpatient drugs at reduced costs. The goal is to support healthcare providers serving vulnerable populations and expand access to care for underserved communities.
How will a rebate model impact cash flow in the 340B drug pricing program?
Under a rebate model, covered entities purchase drugs at full price before receiving reimbursement, which can create temporary cash flow pressure. Delays in claim validation or rebate processing may further impact working capital and financial planning.
What is a rebate in the pharmaceutical industry?
A rebate in the pharmaceutical industry is a financial reimbursement provided by drug manufacturers after a medication is purchased. Rebates are commonly tied to pricing agreements, utilization volumes, or eligibility programs such as Medicaid and 340B.
